Antagonism of P2Y₁₂ or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts

Summary

Platelets activated during experimental acute myocardial infarction (AMI) contribute to myocardial injury. This study aimed to investigate whether platelets from patients with AMI increase myocardial injury after ischaemia and reperfusion in isolated rat hearts and the modification of this effect by the P2Y12 receptor antagonist cangrelor and the glycoprotein IIb/IIIa receptor blocker abciximab. Isolated rat hearts were subjected to 40 minutes of global ischaemia and 60 minutes of reperfusion. Hearts (four simultaneous experiments per patient) were infused with platelets from nine AMI patients (seven thrombolysed, all on aspirin), untreated or incubated with 10 μM cangrelor or 5 μg/ml abciximab. Control experiments were performed using platelets from healthy volunteers and platelet-poor plasma. P-selectin expression on isolated platelets was higher in AMI patients than in controls and was not modified by the treatments. Control platelets or platelet-poor plasma did mild or no harm. In contrast, platelets from AMI patients significantly augmented myocardial injury, as demonstrated by worse left ventricular (LV) developed pressure, higher maximal LV end-diastolic pressure and coronary resistance, and greater lactate dehydrogenase release and infarct size. Both cangrelor and abciximab greatly attenuated these effects. In conclusion, activated platelets from AMI patients increase myocardial injury after ischaemia and reperfusion, and cangrelor and abciximab attenuate this effect. The results support the notion that very early antiplatelet treatment might reduce infarct size by direct effects on reperfused myocardium in these patients.

Keywords

Ischaemia - microcirculation - platelets - reperfusion - antithrombotic agents

• References

• 1 Jørgensen L, Hovig T, Rowsell HC. et al Adenosine diphosphate-induced platelet aggregation and vascular injury in swine and rabbits. Am J Pathol 1970; 61: 161-176.
• 2 Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004; 61: 498-511.
• 3 Garcia-Dorado D, Agulló L, Sartorio CL. et al Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost 2009; 101: 635-642.
• 4 Laws KH, Clanton JA, Starnes VA. et al Kinetics and imaging of indium-111-la-beled autologous platelets in experimental myocardial infarction. Circulation 1983; 67: 110-116.
• 5 Barrabés JA, Garcia-Dorado D, Soriano B. et al Dynamic intracoronary thrombosis does not cause significant downstream platelet embolization. Cardiovasc Res 2000; 47: 265-273.
• 6 Mirabet M, Garcia-Dorado D, Inserte J. et al Platelets activated by transient coronary occlusion exacerbate ischemia-reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol 2002; 283: H1134-1141.
• 7 Barrabés JA, Garcia-Dorado D, Mirabet M. et al Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol 2005; 45: 293-299.
• 8 Takaya N, Katoh Y, Iwabuchi K. et al Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2005; 39: 856-864.
• 9 Xu Y, Huo Y, Toufektsian MC. et al Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290: H692-699.
• 10 Weig HJ, Bott-Flügel L, Städele C. et al Impaired platelet function reduces myocardial infarct size in Galphaq knock-out mice in vivo. J Mol Cell Cardiol 2008; 44: 143-150.
• 11 Ault KA, Cannon CP, Mitchell J. et al Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634-639.
• 12 Mathur A, Robinson MS, Cotton J. et al Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85: 989-994.
• 13 Michelson AD, Barnard MR, Krueger LA. et al Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 1533-1537.
• 14 Frossard M, Fuchs I, Leitner JM. et al Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 1392-1397.
• 15 Barrabés JA, Mirabet M, Agulló L. et al Platelet deposition in remote cardiac regions after coronary occlusion. Eur J Clin Invest 2007; 37: 939-946.
• 16 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 17 Tam SH, Sassoli PM, Jordan RE. et al Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and avß3 integrins. Circulation 1998; 98: 1085-1091.
• 18 Neumann FJ, Zohlnhöfer D, Fakhoury L. et al Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-1426.
• 19 Kupatt C, Habazettl H, Hanusch P. et al c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen: implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 2000; 20: 2226-2232.
• 20 Storey RF, Judge HM, Wilcox RG. et al Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-494.
• 21 Neumann FJ, Blasini R, Schmitt C. et al Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98: 2695-2701.
• 22 Antman EM, Giugliano RP, Gibson CM. et al Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-2732.
• 23 Chen ZM, Jiang LX, Chen YP. et al Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 24 De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008; 100: 184-195.
• 25 Lev EI, Kornowski R, Vaknin-Assa H. et al Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2008; 101: 435-439.
• 26 Wang K, Zhou X, Zhou Z. et al Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model. Arterioscler Thromb Vasc Biol 2003; 23: 357-362.
• 27 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
• 28 Zeymer U, Gitt A, Jünger C. et al Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial infarction. Thromb Haemost 2008; 99: 155-160.
• 29 Barrabés JA, Garcia-Dorado D, Mirabet M. et al Lack of effect of glycoprotein IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. J Am Coll Cardiol 2002; 39: 157-165.
• 30 Sakuma T, Sari I, Goodman CN. et al Simultaneous integrin avß3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty. Cardiovasc Res 2005; 66: 552-561.
• 31 Scirica BM, Sabatine MS, Morrow DA. et al The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. J Am Coll Cardiol 2006; 48: 37-42.
• 32 Massberg S, Enders G, Leiderer R. et al Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-515.
• 33 Massberg S, Enders G, Matos FC. et al Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 1999; 94: 3829-3838.
• 34 Gawaz M, Neumann FJ, Dickfeld T. et al Vitronectin receptor (v 3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 1997; 96: 1809-1818.
• 35 Lefer AM, Campbell B, Scalia R. et al Synergism between platelets and neutrophils in provoking cardiac dysfunction after ischemia and reperfusion: role of selectins. Circulation 1998; 98: 1322-1328.
• 36 Rösen R, Dausch W, Beck E. et al Platelet induced aggravation of acute ischaemia in an isolated rabbit heart model. Cardiovasc Res 1987; 21: 293-298.
• 37 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 02: 349-360.
• 38 Barrabés JA, Garcia-Dorado D, Oliveras J. et al Intimal injury in a transiently occluded coronary artery increases myocardial necrosis: effect of aspirin. Pflugers Arch 1996; 432: 663-670.
• 39 Libersan D, Quan E, Merhi Y. et al Intravenous aspirin at reperfusion does not reduce infarct size in the dog with a residual critical stenosis. J Cardiovasc Pharmacol 1999; 34: 575-583.
• 40 Harrington RA, Stone GW, McNulty S. et al Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
• 41 Greenbaum AB, Ohman EM, Gibson CM. et al Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J 2007; 154: 702-709.
• 42 Van't Hof AW, Ten Berg J, Heestermans T. et al Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008; 372: 537-546.
• 43 Ellis SG, Tendera M, de Belder MA. et al Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-2217.
• 44 Peter K, Schwarz M, Ylänne J. et al Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (IIb 3) inhibitors. Blood 1998; 92: 3240-3249.
• 45 Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-446.